MEG3 and prostate carcinoma: MEG3 showed potential effects on prostate cancer, colorectal cancer, and cancer pathways (Fig. 9a), MIR7-3HG demonstrated potential role in small cell lung cancer, prostate cancer, and cancer pathways (Fig. 9b), FAM95B1 was closely related to endometrial cancer, non-small cell lung cancer, renal cell carcinoma, and MTOR signalling pathway (Fig. 9c), while EPB41L4A-AS1 was associated with small cell lung cancer, prostate cancer, and JAK/STAT signalling pathway (Fig. 9d).